TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib.

Wu, Dandan; Yang, Xuexian O

Wu, Dandan; Yang, Xuexian O.

Wu D; Department of Molecular Genetics and Microbiology, University of New Mexico School of Medicine, Albuquerque, NM, 87131, USA; College of Agronomy, Hunan Agricultural University, Changsha, Hunan, 410128, China.
Yang XO; Department of Molecular Genetics and Microbiology, University of New Mexico School of Medicine, Albuquerque, NM, 87131, USA. Electronic address: xyang@salud.unm.edu.

J Microbiol Immunol Infect ; 53(3): 368-370, 2020 Jun.

Article in English | MEDLINE | ID: covidwho-833053

ABSTRACT

ABSTRACT

COVID-19 emerges as a pandemic disease with high mortality. Development of effective prevention and treatment is an urgent need. We reviewed TH17 responses in patients with SARS-CoV-2 and proposed an FDA approved JAK2 inhibitor Fedratinib for reducing mortality of patients with TH17 type immune profiles.

Subject(s)

Coronavirus Infections/drug therapy; Cytokine Release Syndrome/drug therapy; Janus Kinase 2/antagonists & inhibitors; Pneumonia, Viral/drug therapy; Pyrrolidines/pharmacology; Sulfonamides/pharmacology; Th17 Cells/immunology; Betacoronavirus/immunology; COVID-19; Coronavirus Infections/pathology; Cytokines/biosynthesis; Cytokines/immunology; Humans; Pandemics; Pneumonia, Viral/pathology; SARS-CoV-2

Keywords

COVID-19; Cytokine storm; JAK2 inhibitor; SARS-CoV-2; TH17

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Pyrrolidines / Sulfonamides / Coronavirus Infections / Janus Kinase 2 / Th17 Cells / Cytokine Release Syndrome Limits: Humans Language: English Journal: J Microbiol Immunol Infect Journal subject: Allergy and Immunology / Microbiology Year: 2020 Document Type: Article Affiliation country: J.jmii.2020.03.005

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google